Psoriasis is the skin disease that most frequently affects the nails. Depending on the very
nail structure involved, different clinical nail alterations can be observed. Irritation of the …

Onychomycosis continues to be the most challenging disease condition for pharmaceutical
scientists to develop an effective drug delivery system. Treatment challenges lie in …

Background Apremilast (APM) is a novel, orally administered small molecule drug approved
for treatment of psoriasis or psoriatic arthritis. Due to its low solubility and permeability, it is …

Apremilast, a BCS class IV drug, has minimal solubility in aqueous medium which results in
poor bioavailability. With an intention of enhancing the bioavailability, amorphous solid …

The fungal disease of the nail, onychomycosis, which is also the most prevalent nail
disturbance, demands effective topical treatment options considering the possible adverse …

Apremilast, an orally administered small molecule inhibitor of phosphodiesterase 4 (PDE4),
has been licensed by the US Food and Drug Administration for the management of active …

Liposomes are associated with problems related to stability such as aggregation, fusion,
leakage, and sedimentation on storage [9]. Niosomes are non-ionic surfactant based …

Nail psoriasis (NP) and nail lichen planus (NLP) can be limiting, stigmatizing and difficult to
treat. Dermatologists commonly treat psoriasis and lichen planus but when associated …

Apremilast is an anti-inflammatory agent. It has been a flourishing molecule in the field of
dermatology. In the year 2014, Apremilast got its approval for treatment of psoriatic arthritis …

Onychomycosis is a chronic nail disorder consisting of a fungal infection that causes
physical and psychosocial discomfort to patients. However, its treatment remains …